Newton, Massachusetts, USA, April 21, 2026

In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that its Phase 3 SENTRY clinical trial evaluating selinexor in combination with ruxolitinib for myelofibrosis has been selected for a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This recognition highlights the potential impact of the study in addressing unmet medical needs in patients with rare blood cancers, particularly those who are JAK inhibitor–naïve. The trial’s inclusion in a late-breaking session underscores the importance of the data, which could influence future treatment paradigms in myelofibrosis, a condition characterized by bone marrow fibrosis, anemia, and debilitating systemic symptoms.

SENTRY Trial Evaluates Novel Combination Therapy

The Phase 3 SENTRY trial (XPORT-MF-034) is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of once-weekly selinexor (60 mg) combined with ruxolitinib, compared to ruxolitinib alone in patients with myelofibrosis who have not previously received JAK inhibitor therapy. The study focuses on key co-primary endpoints, including ≥35% spleen volume reduction (SVR35) and improvements in total symptom score (TSS) over a 24-week period.

These endpoints are critical indicators of clinical benefit, as splenomegaly and symptom burden significantly impact patient quality of life. Selinexor, a first-in-class oral XPO1 inhibitor, works by blocking nuclear export proteins involved in cancer cell survival, thereby enhancing the therapeutic effect of ruxolitinib. This innovative combination aims to deliver more durable responses and improved symptom control compared to current standard therapies.

Addressing Unmet Needs in Rare Blood Cancer

Advertisement

cGxPJobs Banner

Myelofibrosis remains a challenging disease with limited treatment options, affecting approximately 20,000 patients in the United States and 17,000 in the European Union. Current therapies primarily rely on JAK inhibitors, which can alleviate symptoms but often fail to achieve long-term disease control.

The SENTRY trial seeks to address these limitations by introducing a novel mechanism of action through selinexor, targeting nuclear export dysregulation, a fundamental driver of oncogenesis. If successful, this combination therapy could represent a new frontline treatment option, offering improved outcomes for patients with high unmet clinical needs. Additionally, selinexor is already approved under the brand XPOVIO® for multiple oncology indications, providing a strong foundation for its continued development in new therapeutic areas.

Strategic Implications for Oncology Pipeline

The selection of the SENTRY trial for a late-breaking presentation at ASCO reinforces Karyopharm’s leadership in developing innovative cancer therapies, particularly in targeting rare and difficult-to-treat malignancies. The company’s focus on oral, targeted therapies aligns with broader industry trends toward patient-friendly treatment options that improve adherence and quality of life.

Furthermore, positive outcomes from this trial could support regulatory advancements and expanded indications for selinexor, strengthening Karyopharm’s position in the competitive oncology market. The company continues to advance a robust pipeline targeting multiple cancers, including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma, demonstrating its commitment to delivering transformative therapies across oncology.

Overall, the upcoming ASCO presentation of the Phase 3 SENTRY trial marks a critical milestone for Karyopharm Therapeutics, with the potential to reshape the treatment landscape for myelofibrosis. By combining innovative science with clinical rigor, the company is advancing new therapeutic options that could significantly improve outcomes for patients living with rare hematologic cancers.

Source: Karyopharm Therapeutics press release